Carbidopa
![](/Images/godic/202501/24/Carbidopa.svg5404.png")
![](/Images/godic/202501/24/Carbidopa_ball-and-stick5404.png")
![Carbidopa synthesis:[3][4][5] GB 940596 ; Chemerda et al., U.S. Patent 3,462,536 (to Merck & Co.). L-form: Karady et al., DE 2062285 ; DE 2062332 (1971 to Merck & Co.).](/Images/godic/202501/24/Carbidopa_synthesis.svg5404.png")
Carbidopa (Lodosyn) is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa. This property is significant in that it allows a greater proportion of peripheral levodopa to cross the blood–brain barrier for central nervous system effect.